Healthcare
Cytek Biosciences, Inc.(CTKB)
Live Price
Offline$3.77
-5.28% today
1Y Change
+28.53%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $610.00M
- Revenue Growth
- +0.5%
- EPS Growth
- -1030.4%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cytek Biosciences, Inc. (CTKB) is a Healthcare stock with a market cap of $610.00M and listed on NASDAQ. The stock last traded around $3.77 and up 28.5% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +0.5%, EPS growth of -1030.4%, a dividend yield of 0.0%. What stands out right now is revenue +0.5%, EPS -1030.4%, free cash flow -140.1% with operating margin -20.0% and ROIC -10.2%. Valuation is more restrained than many high-expectation growth names at price/sales 3.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CTKB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.5% vs +7.6% peer median
Operating Margin
Below sector median
-20.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +0.5% and EPS is at -1030.4%, with operating margin around -20.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +12.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +1.5% | +18.0% | +18.0% |
2026 Feb 26, 2026 | +50.0% | +1.8% | -0.5% | +4.1% |
2025 Nov 5, 2025 | -200.0% | +13.2% | +20.0% | +29.7% |
Benchmark Edge
CTKB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CTKB
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CTKB Max Drawdown
-42.94%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CTKB and SPY.
Company Overview
Cytek Biosciences, Inc.
NASDAQ
Cytek Biosciences Inc. is a biotechnology company that specializes in advancing the capabilities of flow cytometry technologies. Its primary function is to develop and deliver transformative, cost-effective products for researchers and clinicians in the life sciences sector. The company is renowned for its full spectrum flow cytometry systems, which allow users to conduct high-parameter cell analysis with higher accuracy and efficiency compared to traditional methods. This technology has significant implications in numerous fields, including immunology, oncology, and stem cell research, thereby supporting efforts in drug discovery, clinical trials, and personalized medicine. Cytek Biosciences Inc.'s offerings play a crucial role in enabling scientific discoveries and advancing public health initiatives. As a prominent player in the biotechnology market, Cytek contributes to pushing the boundaries of what's possible in cellular analysis, fostering breakthroughs that can lead to new therapeutic strategies and medical treatments.
- Leadership
- Dr. Wenbin Jiang Ph.D.
- Employees
- 676
- Street Address
- 47215 Lakeview Boulevard
- Mailing
- Fremont, CA, 94538
- Region
- Fremont, CA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.0
- Price/Book
- 1.8
Growth
- Revenue
- +0.5%
- EPS
- -1030.4%
- Free Cash Flow
- -140.1%
Profitability
- Gross Margin
- 51.8%
- Operating Margin
- -20.0%
- Net Margin
- -33.0%
- ROE
- -18.0%
- ROIC
- -10.2%
Balance Sheet
- Debt/Equity
- 0.10
- Current Ratio
- 5.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.